Zoledronic acid has direct cytotoxic activity on cancer cells, suppresses angiogenesis, inhibits the FGF-2- and VEGF-dependent proliferation of endothelial cells, and inhibits VEGFR-2 in an autocrine cycle [157]. Here, KDR is linked to cancer.